Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients

American Journal of Kidney Diseases

Volumn 48, Issue 3, 2006, Pages 445-455

  Mircescu, Gabriel ^a   Gârneatǎ, Liliana ^a   Ciocâlteu, Alexandru ^a   Golea, Ovidiu ^a   Gherman Cǎprioarǎ, Mirela ^a   Capsa, Dimitrie ^a   Mota, Eugen ^a   Gusbeth Tatomir, Paul ^a   Ghenu, Adrian ^a   Bǎlutǎ, Simona ^a   Constantinovici, Niculae ^a   Covic, Adrian Constantin ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

dosing frequency; Erythropoiesis stimulating agent; hemodialysis (HD); therapeutic equivalence

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ACUTE DISEASE; ANEMIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; INFLAMMATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

ADULT; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 33747612881     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.05.030     Document Type: Article

References (27)

1. European Best Practice Guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 14 suppl 5 (1999) S9-S36
2. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 suppl 2 (2004) Sii1-Sii41
3. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease (2001), National Kidney Foundation, New York, NY 35-49
4. Besarab A., Reyes C.M., and Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 439-446
5. Paganini E.P., Eschbach J.W., Lazarus J.M., et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 26 (1995) 331-340
6. Weiss L. Flexible dosing schemes for recombinant human erythropoietin-Lessons from our daily practice. Nephrol Dial Transplant 16 suppl 7 (2001) S15-S19
7. Weiss L., Clyne N., Fihlho J.D., et al. The efficacy of once-weekly compared with two or three times weekly subcutaneous epoetin β. Results from a randomised controlled multicentre trial. Nephrol Dial Transplant 15 (2000) 2014-2019
8. Locatelli F., Baldamus C., Villa G., et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta. Results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 40 (2002) 119-125
9. Germain M., Venkata Ram C., Bhaduri S., et al. Extended epoetin alfa dosing in chronic kidney disease patients. A retrospective review. Nephrol Dial Transplant 20 (2005) 2146-2152
10. Provenzano R., Bhaduri S., Singh A.K., and PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease. The PROMPT Study. Clin Nephrol 64 (2005) 113-123
11. Grzeszczak W., Sulowicz W., Rutkowski B., et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 20 (2005) 936-944
12. Locatelli F. Once-weekly treatment with epoetin-β. Nephrol Dial Transplant 20 suppl 6 (2005) Svi26-Svi30
13. Besarab A. Optimizing anemia management with subcutaneous administration of epoetin. Nephrol Dial Transplant 20 suppl 6 (2005) Svi10-Svi15
14. Mircescu G., Capşa D., Covic M., et al. Nephrology and renal replacement therapy in Romania-Transition still continues (Cinderella story revisited). Nephrol Dial Transplant 19 (2004) 2971-2980
15. Burdick R.A., Bragg-Gresham J.L., Woods J.D., et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents. The DOPPS. Kidney Int 63 (2003) 2222-2229
16. Fissell R.B., Bragg-Gresham J.L., Woods J.D., et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents. The DOPPS. Kidney Int 65 (2004) 2235-2342
17. Biostatistical methodology in clinical trials in applications for marketing authorizations for medical products. CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN. Available at: http://www.ich.org/pdfICH. Accessed December 2, 2004
18. Mircescu G., Gherman-Cǎprioarǎ M., Covic A., et al. Best Practice Guidelines. Anemia Secondary to Chronic Kidney Disease (2005), Infomedica, Bucharest, Romania
19. Stenvinkel P., Wanner C., Metzger T., et al. Inflammation and outcome in end-stage renal failure. Does female gender constitute a survival advantage?. Kidney Int 62 (2002) 1791-1798
20. Mircescu G., Gherman-Cǎprioarǎ M., Covic M., et al. Best Practice Guidelines. Hyperparathyroidism Secondary to Chronic Kidney Disease (2005), Infomedica, Bucharest, Romania 3
21. Jones B., and Jarvis P. Trials to assess equivalence. The importance of rigorous methods. BMJ 313 (1996) 36-39
22. Piccoli A., Malagoli A., Komninos G., and Pastori G. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol 15 (2002) 565-574
23. Nomoto Y., Kawaguchi Y., Kubota M., et al. A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int 14 (1994) 56-60
24. Macdougall I.C. Optimizing the use of erythropoietic agents-Pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 17 suppl 5 (2002) S66-S70
25. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 suppl 3 (2001) S3-S13
26. Locatelli F., Pisoni R.L., Combe C., et al. Anemia in hemodialysis patients of five European countries. Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 121-132
27. Valderrábano F., Hörl W.H., Jacobs C.L., et al. Patients and methods. Nephrol Dial Transplant 15 (2000) 2-7